- See:
-
Penicillin Family
-
AntiPseudomonal Agents
- Discussion:
- piperazine penicillin derivative with increased activity against many gm negative bacteria -
P.aeruginosa, Enterobacteriacae - S.faecalis; Anaerobes (B.fragilis);
- for serious infect.: 200-300 mg/kg/24hr IV in 4-6 divided doses;
- for complicated
UTI: 125-200 mg/kg/day given IV in 3-4 div. doses;
- for uncomplicated
UTI and community aquired pneumoniae: 100-125mg/kg IV in 2-4 divided doses;
- note must decrease dose w/ renal failure: 1.85mEq Na/gm;
- Dose for70 kg Adult: gm/dosing interval in hrs: CrCl: >80: 3/4; CrCl:50-79::3/4; CrCl:30-49::3/6; CrCl:10-29::2/6-8;
- 70-90% of drug will be excreted in to urine (w/ nl RF(x))
- peds: 200-300 mg/kg/day q6hr;
- note possible convulsions;
- will interact with
aminoglycosides, oral anticoagulants, OC;
- interaction w/
cefoxitin: antagonism vs
pseudomonas;
- piperacillin is more potent than
ticarcillin against
P. aeruginosa and
Klebsiella, but has activity
similar to that of
ticarcillin against most other gram-negative pathogens.
-
zosyn: includes the addition of tazobactam to piperacillin;
- this addition will help to combat antimicrobial resistance;
- dose: 3.375 mg IV q 6-8 hours;
Piperacillin/tazobactam therapy for diabetic foot infection.
AM Zeillemaker Md et al.
Foot and Ankle. Vol 19. No 3. March 1998. p 169.
